Is upfront stereotactic radiosurgery a rational treatment option for very elderly patients with brain metastases? A retrospective analysis of 106 consecutive patients age 80 years and older by Shoji Yomo & Motohiro Hayashi
RESEARCH ARTICLE Open Access
Is upfront stereotactic radiosurgery a
rational treatment option for very elderly
patients with brain metastases? A
retrospective analysis of 106 consecutive
patients age 80 years and older
Shoji Yomo1,2* and Motohiro Hayashi2
Abstract
Background: Advanced age has been shown to be a factor predicting poor survival in patients with brain
metastases (BM). There have been only a few studies focusing on stereotactic radiosurgery (SRS) for elderly BM
patients. The present study aimed to investigate the efficacy and limitations of SRS for very elderly BM patients.
Methods: This was a retrospective observational study analyzing 106 consecutive patients (69 males/37 females)
age 80 years and older who received upfront Gamma Knife SRS for BM between January 2009 and October 2015.
The median age was 84 years, and the median Karnofsky performance status (KPS) was 70. Fifty-two patients had a
solitary BM, and others multiple BM. The median cumulative tumor volume was 3.9 mL and the median dose
prescribed was 20 Gy. Overall survival (OS), neurological death rates and distant and local intracranial tumor control
rates were analyzed.
Results: No patients were lost to follow-up. Six-month and 12-month OS rates were 54% and 32%, respectively.
The median OS time was 7.1 months. Competing risks analysis showed that 6-month and 12-month neurological
death rates were 8% and 11%, respectively. In total, 245 / 311 tumors (79%) in 82 patients (77%) with sufficient
radiological follow-up data were evaluated. Six-month and 12-month distant BM recurrence rates (per patient) after
SRS were 17% and 25%, respectively. Six-month and 12-month rates of local tumor control (per lesion) were 94%
and 89%, respectively. Repeat SRS, salvage WBRT and surgical resection were subsequently required in 25, 4 and 1
patient, respectively. Proportional hazard regression analysis showed that KPS ≥ 70 (HR: 0.444, P < .001), controlled
primary disease/no extracranial metastases (HR: 0.361, P < .001) and female sex (HR: 0.569, P = 0.028) were independent
factors predicting better OS. Similarly, tumor volume (>2 mL) was the only factor predicting a higher rate of local
control failure (HR: 12.8, P = 0.003).
Conclusions: The present study suggested an upfront SRS strategy to offer a feasible and effective treatment
option for very elderly patients with limited BM. In the majority of patients, neurological death could be delayed
or even prevented.
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Background
In industrial nations, demographic projections portend a
substantial increase in numbers of older persons, thus im-
plying consequent increases in cancer incidence and mor-
tality in the elderly [1]. Advanced age has been shown to
be an important prognostic factor for survival in patients
with brain metastases (BM) [2–6]. Diminished per-
formance status and the presence of co-morbidities
may make radiotherapy less feasible in the elderly.
Moreover, elderly patients may prefer less aggressive
treatment for BM. In fact, palliative whole brain radio-
therapy (WBRT) utilization rates drop steeply in the
elderly [7]. Recently, in selected patients, WBRT has
been omitted from the initial management for BM with
the aim of reducing the potential risk of delayed neuro-
logical toxicity [8–10]. Stereotactic radiosurgery (SRS)
has emerged as the preferred treatment modality, either
alone or in combination with other modalities [10, 11].
The delivery of highly focused radiation with a sharp dose
fall-off is theoretically expected to reduce delayed neuro-
toxicity, and this feature makes it applicable in both the
upfront and the salvage setting. To date, a few studies
have investigated SRS treatment results for elderly patients
with BM, but the definitions of elderly patients differed
among these prior SRS studies (Table 1) [12–16]. We con-
sider evidence for the clinical efficacy of SRS for elderly
patients with BM to still be insufficient and advocate add-
itional research to confirm the therapeutic benefits of SRS
in this population.
Thus, the efficacy and limitations of our SRS-oriented
treatment strategy for very elderly patients, i.e. those at
least 80 years of age, with newly diagnosed and/or recur-
rent BM were investigated. The present study also ex-




The present study was conducted in compliance with
the Declaration of Helsinki (sixth revision, 2008), and
fulfilled all of the requirements for patient anonymity.
The Aizawa Hospital Institutional Review Board ap-
proved this retrospective clinical study in October 2015
(No. 2015–038).
We analyzed our prospectively maintained institu-
tional radiosurgical database to examine the radio-
logical and clinical outcomes. Between December 2008
and October 2015, 106 consecutive very elderly patients
with BM who underwent Gamma Knife SRS as upfront
treatment were eligible for the present study. During
this study period, 2 patients receiving prior WBRT be-
fore SRS were identified and excluded. Of the eligible
patients, 69 were male and 37 were female. The median
age was 84 years (range: 80–93 years). The median
Karnofsky performance status (KPS) at the time of SRS
was 70 (range: 30–100). The primary cancers were of
the lung in 74 patients (including 8 with small cell lung
cancer), the digestive tract in 16, melanoma in 3, the
breast in 2, the kidney in 2, the thyroid in 2, the ovary
in 1, and were of unknown origin in 6 patients. Before
SRS, 7 patients had undergone microsurgical resection
of BM and one had received an endoscopic third ventri-
culostomy for obstructive hydrocephalus. The median
interval between primary diagnosis and SRS was
11.3 months (range: 0–246 months). Patient character-
istics are summarized in Table 2.
Radiosurgical Indications and Techniques
One hundred and three (97%) patients included in the
present study had been diagnosed and their primary tu-
mors treated at the referring regional hospitals, whose



















Noël, 2005 [12] LINAC 117 71 years
(≥65 years)






Kim, 2008 [13] LINAC/GK 44 79 years
(≥75 years)
17 (39%) a7.3 Single BM b88% b81%
Minniti, 2013
[14]
LINAC 102 77 years
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4 (2%) 5.3 NR b95% NR
Park, 2015 [16] GK 147 79 years
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GK 106 84 years
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SRS stereotactic radiosurgery, BM brain metastasis, WBRT whole brain radiotherapy, MST median survival time, LINAC linear accelerator, GK gamma knife, atime
from the diagnosis, bcrude value, NR not reported
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own cancer boards had provisionally determined the ap-
propriateness of SRS. The patients were then referred to
our institution to receive SRS for BM. The remaining
three patients had been treated at our institution. The
SRS protocol used in this study was based on the stand-
ard care established at our institution. Patients with up
to ten BM principally received SRS. Providing that
WBRT had been refused by the patient, SRS was applied
for multiple BM, even in cases with more than 10 le-
sions, when the patient’s systemic condition was such
that SRS intervention would be tolerable and fully
informed consent for treatment had been obtained.
Surgical resection was, in principle, indicated for large
tumors with a mass effect. If surgery did not seem feas-
ible due to a poor prognosis or advanced systemic dis-
ease, 2-session SRS was indicated for carefully selected
large tumors (≥10 mL) [17].
SRS was performed using the Leksell G stereotactic frame
(Elekta Instruments, Stockholm, Sweden). The frame was
placed on the patient’s head under local anesthesia supple-
mented with mild sedation. Three-dimensional volumetric
gadolinium-enhanced T1-weighted magnetic resonance
(MR) images, 2 mm in thickness, T2-weighted MR im-
ages and contrast-enhanced computed tomography
covering the whole brain were routinely used to gener-
ate a treatment plan with Leksell Gamma Plan software
(Elekta Instruments). Prescribed doses were selected in
principle according to the dose protocol of the JLGK
0901 study [10]. The technical details of 2-session SRS
were previously described in detail [17]. Total prescrip-
tion doses in 2-session SRS were recalculated into a
single dose applying a linear-quadratic (LQ) model by
assuming the alpha/beta ratio to be 10 for BM [18]. All
treatments were performed with the Leksell Gamma
Knife Model C or Perfexion.
Post-SRS Management and Follow-up Evaluation
Clinical follow-up data as well as contrast-enhanced MR
images were obtained every one to three months. If
metachronous distant metastases were identified, they
were, in principle, managed with repeat SRS. When mil-
iary metastases (numerous tiny enhanced lesions) and/or
leptomeningeal carcinomatosis was newly documented,
WBRT was then recommended. Local control failure
was defined as an at least 20% increase in the diameter
of the targeted lesions, taking as a reference the pre-SRS
diameter, irrespective of whether the lesion was a true
recurrence or delayed radiation injury. We endeavored
to meticulously differentiate delayed radiation injury
from tumor recurrence, based on serial MR imaging
findings [19] and the clinical course. Additional SRS was
possible provided that the volume of the local tumor re-
currence was small enough for single-dose SRS. Surgical
removal was indicated when neurological signs became
refractory to conservative management, regardless of
whether the radiological diagnosis was local tumor pro-
gression or radiation necrosis. Any adverse events attrib-
utable to SRS procedures were evaluated based on the
National Cancer Institute Common Terminology Criteria
for Adverse Events (NCI-CTCAE; ver.4.0).
Before closing the research database for analysis in
August 2016, the authors updated the follow-up data of
patients who had not visited our outpatient department
for more than three months. Inquiries about the date
and mode of death were made by directly corresponding
with the referring physician and/or the family of the de-
ceased patient, with written permission obtained at the
time of undertaking SRS from all patients and/or their
relatives, allowing the use of personal data for clinical re-
search. Neurological death was defined as death attribut-
able to central nervous system metastases including
tumor recurrence and carcinomatous meningitis. Deaths
with unspecified causes were also categorized as neuro-
logical deaths in the present study.
Statistical analysis
The overall survival (OS) rate was calculated by the
Kaplan-Meier product limit method. The neurological
and non-neurological death rates were calculated
employing Gray’s test [20], wherein each event was
regarded as a competing risk for another event. For the
estimation of local control failure rates and distant BM
recurrence, Gray’s test was similarly applied, with subse-
quent WBRT for distant recurrence and the patient’s
death being regarded as competing events, respectively.
All of the above analyses were based on the interval
from the date of initial SRS treatment until the date of




Age (years), median (range) 84 (80–93)
KPS, median (range) 70 (30–100)
Controlled primary disease and no extracranial
metastases
25 (24%)
RTOG-RPA class II/class III 56/50
Ongoing systemic chemotherapy 31 (29%)
Time from primary diagnosis to initial
SRS (months), median (range)
11.3 (0–246)
Cumulative TV on initial SRS (mL), median
(range)
3.9 (0.2–53.3)
No. of intracranial lesions at initial SRS, median (range) 2 (1–16)
No. of patients treated with 2-session SRS 15 (14%)
KPS Karnofsky performance status, RTOG radiation treatment oncology group,
RPA recursive partitioning analysis, SRS stereotactic radiosurgery, TV
tumor volume
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each event. The Cox and Fine-Gray proportional hazards
models [21] were appropriately employed to investigate
prognostic factors associated with OS and neurological
death-free survival, and for local tumor control. Potential
prognostic factors were selected with reference to other
SRS series [12–14, 16, 22, 23]. The statistical processing
software package “R” version 3.0.1 (The R Foundation for
Statistical Computing, Vienna, Austria) was used for all
statistical analyses. A P-value < 0.05 was considered to in-
dicate a statistically significant difference.
Results
Eighty-one patients (76%) had active systemic disease
and/or extracranial metastases and 31 (29%) were receiv-
ing systemic chemotherapy around the time of the initial
SRS. Sixteen patients (15%) received molecular targeted
therapy, and 12 patients with epidermal growth factor
mutation positive lung adenocarcinoma were adminis-
tered oral tyrosine kinase inhibitors. Fifty-two patients
(49%) had solitary BM. The median number of BM at
the initial SRS was 2 (range: 1–16 tumors). In total, 311
tumors were being treated at the time of the initial SRS.
The median tumor volume (TV) was 0.4 mL (range:
0.01–53.3 mL) and the median cumulative TV was
3.9 mL (range: 0.2–53.3 mL). The median prescribed
dose for single-session SRS was 20 Gy (range: 15–
22 Gy). Fifteen patients (14%) with 17 large tumors were
allocated to 2-session SRS. The median TV of large BM
treated with 2-session SRS was 17.9 mL (range: 10.1–
53.3) and the median cumulative dose prescribed was
27 Gy (range: 20–28). By the time of the second session,
the median TV had been reduced to 8.6 mL (range: 2.3–
42.6).
Full clinical results were available for all 106 patients
as follow-up data had been completely updated in all
patients. The median follow-up time after SRS was
7.1 months (range: 0.3–64 months). At the time of as-
sessment, 11 patients (10%) were alive and 95 (90%)
had died. The cause of death in 77 patients was pro-
gressive systemic cancer or related complications (e.g.:
acute respiratory failure, liver insufficiency) and one
patient died from severe head trauma not associated
with either the systemic cancer or BM. Eleven patients
died as a consequence of their BM and in the
remaining 6 the cause of death could not be specified.
The median survival time (MST) was 7.1 months (95%
CI: 4.6–8.7). Six-month and 12-month OS rates after
SRS were 54% and 32%, respectively (Fig. 1). Eleven of
these 106 (10%) elderly patients survived more than
2 years after SRS. The Cox proportional hazards model
for OS identified KPS ≥ 70 (Hazard ratio (HR): 0.444,
95% confidence interval (CI): 0.284–0.715, P < .001)
(Fig. 2a), controlled primary and no extracranial me-
tastasis (HR: 0.361, 95% CI: 0.206–0.632, P < .001)
(Fig. 2b) and female sex (HR: 0.569, 95% CI: 0.344–
0.942, P = 0.028) (Fig. 2c) as favorable factors inde-
pendently predicting better OS rates (Table 3). Six-
month and 12-month neurological death probabilities
adjusted for competing events (non-neurological
death) were 8% and 11%, respectively (Fig. 1). No
factors were identified as being statistically signifi-
cantly associated with higher risk of neurological
death by the Fine-Gray proportional hazards model
(Table 4).
Only the 245/311 tumors (79%) in 82 patients (77%)
who had sufficient radiological follow-up data were ana-
lyzed herein because the other 24 patients died from sys-
temic disease progression without follow-up MR
imaging studies. Distant metachronous BM were ob-
served in 25 patients (24%). Six-month and 12-month
distant BM recurrence rates (per patient) after SRS were
17% and 25%, respectively (Fig. 3a). Six-month and 12-
month local tumor control rates (per lesion) were 94%
and 89%, respectively (Fig. 3b). Fifteen BM were eventu-
ally diagnosed as local tumor recurrence at a median
time of 4.7 months after SRS (range: 3.4–12.8 months).
A sub-analysis of 2-session SRS conducted for large tu-
mors found a durable TV reduction coupled with symp-
tom relief for 14 of 17 tumors (82%). Three large tumors
recurred after initially being responsive to SRS and sal-
vage SRS was thus conducted between 4.7 months and
12.8 months after the initial treatment. The proportional
Fig. 1 Survival results for very elderly (≥80 years of age) patients
with BM treated with SRS. The solid line represents overall survival
(OS) probability. The median survival time (MST) was 7.1 months
(95% CI: 4.6–8.7). Six-month and 12-month OS rates after SRS were
54% and 31%, respectively. The dotted line represents the neurological
death-free survival (NS) probability adjusted for competing events.
Six-month and 12-month NS rates after SRS were 92% and 89%,
respectively. Note that the distance between these two lines, NS and
OS, represents the cumulative incidence of non-neurological death
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hazards model demonstrated TV larger than 2 mL (HR:
12.8, 95% CI: 2.32–69.3, P = 0.003) to be the only factor
predicting a higher rate of local control failure (Table 5)
(Fig. 3c).
Twenty-five patients (24%) required repeat SRS for
distant or local BM recurrence. The total number of SRS
sessions ranged up to 8 and the total number of BM
treated per patient ranged up to 42. Four patients (4%)
underwent salvage WBRT between 2.6 and 22.6 months
after SRS because of subsequent development of miliary
BM and/or leptomeningeal dissemination. One patient
had to undergo surgical resection under a provisional
diagnosis of symptomatic local recurrence 6.6 months after
SRS and the histopathological diagnosis was radiation ne-
crosis which predominated over viable adenocarcinoma.
Regarding adverse radiation effects, we experienced
one case of radiation-induced optic nerve neuropathy
(CTCAE grade 4), secondary to salvage SRS for meta-
chronous recurrence around the left optic canal. Prior to
intervention, this patient had been informed of the pre-
dicted risk to the affected optic nerve and consented to
undergo the intervention. Repeat seizures occurred and
newly required anticonvulsive therapy in 3 patients
(CTCAE grade 3). Two patients required prolonged oral
steroids for delayed symptomatic radiation necrosis
(CTCAE grade 2). Tumor-related hemorrhage was ob-
served in 5 patients (3 melanomas, 1 lung adenocarcin-
oma and 1 renal cell carcinoma) and one of these was
mildly symptomatic but eventually showed clinical and
radiological stabilization (CTCAE grade 2).
Discussion
Current demographic changes as the rationale for
the present study
Over the past few decades, the longest extension in life
expectancy worldwide has been observed in Japan [24].
World Health Statistics 2014 published by the WHO
Fig. 2 Overall survival (OS) results stratified according to independent prognostic factors. KPS≥ 70 (Hazard ratio (HR): 0.444, P < .001) (a). Controlled
primary disease/no extracranial metastases (HR: 0.361, P < .001) (b). Female sex (HR: 0.569, P = 0.028) (c)
Table 3 Analysis of factors predicting patient survival after SRS
(Cox proportional hazards model)
Covariate (No. of patients) MST
(months)
P value Hazard ratio
(95% CI)
Sex 0.028 0.569 (0.344–0.942)
Female (37) 8.9
Male (69) 4.7
KPS < .001 0.444 (0.279–0.706)
KPS≥ 70 (56) 9.7




< .001 0.361 (0.206–0.632)
Yes (25) 18.0
No (81) 4.7
Interval from primary diagnosis
to SRS
0.053 0.687 (0.448–1.05)
Long > 12 months (54) 8.8
Short≤ 12 months (52) 4.4
Chemotherapy 0.806 1.08 (0.603–1.92)
Yes (31) 12.8
No (75) 5.2
No. of metastases 0.513 0.864 (0.557–1.34)
Solitary (52) 6.9
Multiple (54) 7.1
Cumulative PIV 0.375 1.25 (0.762–2.06)
Small≤ 5 mL (45) 7.7
Large > 5 mL (61) 5.4
Type of intervention 0.269 1.47 (0.744–2.89)
Two-session (15) 4.0
Single session (91) 7.2
SRS stereotactic radiosurgery, MST median survival time, CI confidence interval,
KPS Karnofsky performance scale, PIV prescription isodose volume
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showed the life expectancies at birth of Japanese men
and women to both exceed 80 years [25]. The definition
of elderly, when discussing patients with cancer, varies.
In many previous studies of SRS for elderly patients with
BM, the cut-off ages were set between 65 and 75 years
(Table 1) [12–14, 16]. In our country, cancer patients in
their 70s are no longer seen as the elderly requiring spe-
cial care and significant proportions of those age 80 years
and older still receive active anti-cancer treatments, as
described in the present study. Together with advances
in the development of systemic treatments, the long-
term control of intracranial disease has become increas-
ingly important not only for overall disease control but
also for the patient’s quality of life. However, it is not
uncommon for elderly patients to have multiple, concur-
rent diseases restricting their physiological reserves as
well as age-related cognitive decline [16]. Elderly pa-
tients with cancer are, in general, less likely to receive
definitive therapy and their decisions about treatment
may also be influenced by nonmedical, potentially cor-
rectable factors such as impaired social services support
for those receiving treatment [26].
Few, if any, studies have investigated SRS treatment re-
sults for very elderly patients, i.e. those at least 80 years
of age, with BM [15] and this aged population has been
under-represented in clinical trials of cancer therapy,
even in the era of targeted therapy. Thus, the authors
considered the age of 80 years to be a reasonable cut-off
point, given that the present study aimed to investigate
the efficacy and the limitations of comprehensive man-
agement of SRS for BM in the very elderly patient
population.
Survival after SRS of elderly patients with BM
The MST slightly longer than 7 months demonstrated
herein appears to be shorter than in previous studies of
SRS series investigating different patient cohorts con-
ducted in the authors’ institutions [23, 27, 28]. This
observation may support age being an important prog-
nostic factor in the majority of patients with malignant
primary or metastatic brain tumors, [2, 3]. Watanabe et
al. also demonstrated in their case-matched study that
post-SRS MST was, in fact, slightly shorter in patients
80 years of age and older than in those 65–79 years of
age, although the difference did not reach statistical sig-
nificance. The OS results after SRS in the present study
seemed to be comparable to those of previous studies
(Table 1). Minniti et al. reported an exceptionally better
OS rate than in other studies. This might be attribut-
able to patient selection criteria such as their adoption
of an age cut-off of 70 years, oligometastases (1–4 BM),
exclusion of small cell lung cancer, and so on. The
present study placed priority on generalizability by
Table 4 Analysis of factors predicting neurological death-free
survival after SRS (Fine-Gray proportional hazards model)
Covariate P value Hazard ratio (95% CI)
Female Sex 0.20 0.443 (0.129–1.53)




Long interval from primary diagnosis
to SRS (>12 months)
0.48 1.41 (0.549–3.60)
Chemotherapy 0.25 0.423 (0.097–1.84)
Solitary metastasis 0.21 0.534 (0.206–1.42)
Small cumulative PIV (≤5 mL) 0.15 0.438 (0.144–1.33)
Two-session SRS 0.26 0.426 (0.095–1.91)
SRS stereotactic radiosurgery, CI confidence interval, KPS Karnofsky
performance scale, PIV prescription isodose volume
Fig. 3 Distant intracranial recurrence rate (a), overall local tumor control rate (b) and local tumor control rates stratified according to the tumor
volume (TV) (c). Six-month and 12-month distant intracranial recurrence rates (per patient) were 17% and 25%, respectively. Six-month and 12-month
local tumor control rates (per lesion) were 94% and 89%, respectively. TV larger than 2 mL was the only factor predicting a higher rate of local control
failure (HR: 12.8, P = 0.003)
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including all consecutive cases, even those with large
multiple BM and/or very low KPS, and thus reflects the
contemporary situation of patients with BM in the
community.
Prognostic factors and selection of candidates for SRS
among elderly patients with BM
Identifying factors predicting longer survival in patients
with BM is critically important for assigning patients to
the optimal treatment modality. In our patient cohort,
higher KPS (≥70) (Fig. 2a), controlled primary disease/
no extracranial metastases (Fig. 2b) and female sex
(Fig. 2c) were independently associated with better pa-
tient survival in multivariate analyses (Table 3). High
KPS scores and systemic disease control have already
been validated in large prospective datasets from radi-
ation therapy oncology group (RTOG) trials [2, 5], as
well as being reproduced in prior studies focusing on
elderly patients (Table 1). Regarding female sex, we
speculate that this might be attributable to the difference
in the prevalence of molecular targeted therapy use
between males and females. In our patient cohort, 14 of
16 patients receiving molecular targeted therapy were
female. Although not shown in the results because these
observations are quite preliminary, patients treated with
molecular targeted therapy had longer survival than
those not receiving such treatments (16.9 months vs.
5.8 months, log-rank test, P = 0.007). The emerging role
of combining SRS and molecular targeted therapy merits
future investigation. Our observations suggest that se-
lected subsets of patients can be expected to experience
prolonged survival, although the expected survival may
be limited in the majority of elderly patients with BM.
The long interval from primary diagnosis to SRS was of
borderline significance in the multivariate analysis (P =
0.053). This might, at least in part, be attributable to pa-
tients with a long prior disease history having been self-
selected to do well by virtue of having had time to de-
velop BM and not dying of their systemic disease due to
inherently indolent cancers.
The mode of death and its clinical significance
Concerning the cause of death, many of these patients
actually died of extracranial disease progression, as
demonstrated herein. Given this observation, OS may
not be an appropriate endpoint for accurately evaluating
the efficacy and limitations of SRS for BM. The authors
believe it to be important to measure how SRS might
delay or even prevent worsening neurological symptoms
and eventually neurological death regardless of the pa-
tient’s age, while adequately maintaining the patient’s
quality of life. From this viewpoint, clinical information
about the mode of death and the local control of BM is
indispensable. Understanding potential differences in the
mode of death, is anticipated to facilitate answering the
important question of whether treating BM delays
neurological progression long enough to allow for a
comfortable remaining life. The present study showed
that neurological death could be delayed or even pre-
vented by SRS in the majority of very elderly patients
with BM, although the observed OS was still limited.
Unfortunately, no risk factors clearly associated with
neurological death were identified herein (Table 3),
probably due to the lack of events of interest. Further
experience needs to be accumulated to identify factors
potentially influencing neurological death.
Importance of follow-up management and salvage
treatment strategies
The local tumor control rate demonstrated herein ap-
peared to be acceptable and was similar to those ob-
tained in previous studies (Table 1) [12–15]. Regarding
factors influencing local tumor control in the present
study, mid-size to large tumors (>2 mL) were more
likely to recur or complicate radiation-induced toxic
events (Table 4). This finding supports prior SRS stud-
ies showing TV to be an important predictor of local
control in patients with BM treated with single-dose
SRS [22, 29, 30]. The present study failed to demon-
strate the relationship between prescription dose and
local control rate. We speculate that one of the reasons
might involve the validity of dose estimation for 2-
session SRS based on the LQ model, which is applied
to adjust for the difference between a single session and
two sessions. There has been controversy as to whether
the LQ model is appropriate for large doses per frac-
tion. Brown et al. recently reported that, for most
tumors, the LQ model is still relevant for explaining
the results obtained from clinical studies of SRS and
stereotactic radiotherapy [31]. On the other hand, the
possibility of additional biological effects resulting from
endothelial cell damage, enhanced tumor immunity, or
both has been suggested [32, 33]. However, we do not
yet have an appropriate model taking into account
these additional factors.
Two-session SRS conducted for large tumors, in fact,
achieved an acceptable local control rate (75% at 1 year)
although it was lower than that of small metastases
Table 5 Analysis of factors predicting local tumor control failure
(Cox proportional hazards model)
Covariate P value Hazard ratio (95% CI)
Large TV (>2 mL) 0.003 12.8 (2.36–69.3)
Tumor causing focal deficit 0.379 1.69 (0.526–5.41)
High marginal dose (≥20Gy) 0.949 1.04 (0.317–3.41)
Two-session SRS 0.946 1.05 (0.284–3.86)
CI confidence interval, TV tumor volume, SRS stereotactic radiosurgery
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(Fig. 3c). Considering the low alpha/beta ratio of the tissue
in the central nervous system and the author’s as yet lim-
ited experience, hypofractionated stereotactic radiotherapy
might be among the potential alternatives for reducing
acute toxicities while improving the local control rate in
patients with mid-size to large tumors. However, the clin-
ical evidence accumulated to date is not yet conclusive
[34, 35]. The potential for improvement of local tumor
control using hypofractionated stereotactic radiotherapy
with a Gamma Knife unit warrants further research.
Subsequent intervention was actually needed in 26
patients (25%), mostly because of distant BM recur-
rence. Most of these cases were successfully managed
with repeat SRS. Hanssens et al. reported that SRS
alone based on high-resolution MR imaging, decreased
the incidence of and increased the time until distant re-
currences [36]. In fact, the competing risks regression
analysis employed herein indicated the rate of salvage
treatment for new BM to be somewhat lower than
those in prior studies (25% at 1 year) [12–14]. Although
there is no general consensus regarding the risks and
benefits of omitting upfront WBRT, it appears that re-
peat radiosurgery may be effective as salvage therapy
for recurrent tumors after SRS alone, especially in eld-
erly patients. Taking into account the detrimental de-
layed effects of WBRT on cognitive function and
health-related quality of life [8, 9, 37], it may be a ra-
tional treatment approach to strategically withhold
WBRT until it would presumably be the most efficient
treatment option [9]. To assure the relevance of SRS
management, meticulous clinical and neuroimaging
follow-up and timely salvage SRS are essential, while it
should be noted that such a treatment strategy does
have the potential to place a major socio-economic bur-
den on elderly cancer patients and their relatives.
Weaknesses of the present study
This study has several limitations. The critical issue in
the present study is patient selection bias inherent to the
retrospective approach. It is possible that elderly patients
with limited numbers of BM in the present study had
developed tolerance to the treatment and also had better
access to our institution and were consequently self-
selected to do well. It must be also appreciated that we
cannot address the potential role of SRS in comparison
to WBRT, given the exploratory nature of the analyses in
a non-comparative study. We could not control for the
possibility that there may have been patients not sent
to us, due to referral bias, whose outcomes could have
differed from what was observed in the present patient
cohort. In follow-up management, some patients con-
tinued to be followed by their referring oncologists.
Neuroimaging protocols could have differed among
these hospitals, and we cannot rule out the possibility
of patients not being referred to our institution even if
tiny intracranial local or distant recurrences were de-
tected in those in poor condition with very short life
expectancies. Therefore, it is necessary to fully recognize
that the rates of local and distant recurrences of BM might
be underestimates. In addition, the relatively small num-
ber of patients and relative heterogeneity of the patient
population may have limited the statistical power of the
analyses, leading to incorrect conclusions. More
evidence-based information obtained from a well-
designed prospective comparative study is needed to
confirm our findings regarding the clinical efficacy of
SRS for elderly patients with BM.
Conclusions
We investigated the efficacy of SRS for BM in a cohort
of very elderly patients and our findings suggested SRS
to be a feasible and effective treatment option even for
those of advanced age with BM. Close follow-up and
continuation of radiosurgical management might con-
tribute to reducing the rate of neurological death. Prog-
nostic factors associated with better OS in our cohort
were high KPS, controlled primary disease/no extracra-
nial metastases and female sex.
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